Combined treatment with a STAT3 inhibitor (cucurbitacin B) and EGFR-TKI (gefitinib) significantly induced cell apoptosis through EGFR and STAT3 pathways in CRC cells [144]. The gene discussed is STAT3; the disease is colorectal carcinoma.